Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

ASTAR: Sacituzumab Govitecan For Breast Cancer (ASTAR)

13. november 2026 opdateret af: Laura M. Spring, MD, Massachusetts General Hospital

A Phase II Study of Adjuvant Sacituzumab Govitecan (SG) in High-risk Early-stage HR+/HER2- Breast Cancer (ASTAR)

The goal of this clinical trial is to assess the safety and tolerability of sacituzumab govitecan followed by docetaxel and cyclophosphamide for individuals with high-risk early-stage HR+/HER2- breast cancer. The main questions it aims to answer are:

  • Is sacituzumab govitecan safe for individuals with this type of cancer?
  • Is sacituzumab govitecan effective in curing this type of cancer? Participants will receive up to 8 cycles of sacituzumab govitecan with chemotherapy.

Studieoversigt

Detaljeret beskrivelse

This is a single-arm, open-label, phase II study evaluating the toxicity and feasibility of sacituzumab govitecan (SG) followed by docetaxel/cyclophosphamide (TC) in patients with high-risk early-stage HR+/HER2- breast cancer. Participants will receive four 21-day cycles of the study treatment, sacituzumab govitecan, and then four 21-day cycles of docetaxel and cyclophosphamide chemotherapy, for a total of eight cycles or 24 weeks. Participants will be followed for up to three years after completing study treatment. It is expected that about 32 people will take part in this research study. Gilead Sciences, Inc., a biopharmaceutical company, is supporting this research study by providing the study drug, sacituzumab govitecan, and funding for research activities. The U.S. Food and Drug Administration (FDA) has not approved sacituzumab govitecan for this specific disease, but it has been approved for use in other stages of breast cancer. Sacituzumab govitecan is a lab-made, humanized monoclonal antibody drug-conjugate. "Humanized" means it is primarily made to look like a natural human antibody, so the body tolerates it better. An antibody is a protein made by your immune system that recognizes and sticks to harmful things like bacteria, viruses, or cancer cells so your body can fight them off. Sacituzumab govitecan is a type of targeted cancer treatment made by linking an antibody that fights cancer cells and a chemotherapy drug that can kill the cancer cells together. Use of an antibody allows the chemotherapy to be delivered directly to cancer cells, helping kill them while reducing damage to the rest of the body. The U.S. FDA has approved docetaxel and cyclophosphamide chemotherapy as a treatment option for this disease. Docetaxel is a type of chemotherapy that works by disrupting the function of microtubules (a hollow "tube" that helps cells keep their shape and pull apart) which helps to stop cell division. Cyclophosphamide is an alkylating agent, a type of chemotherapy medication that works by adding alkyl groups to DNA. Alkyl groups are small chemical pieces that attach to other molecules and change how those molecules work. This interferes with the cells' ability to make copies of itself, causing cell death in rapidly dividing cells, such as cancer cells. Together, docetaxel essentially "freezes" cells so they can't finish dividing and cyclophosphamide damages their DNA so they cannot make new copies, eventually leading to cell death. Using these drugs together helps attack leftover cancer cells in different ways at the same time, helping the treatment to be more effective and killing cancer cells. The U.S. FDA has not approved sacituzumab govitecan followed by docetaxel and cyclophosphamide chemotherapy as a treatment option for this disease.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

32

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Massachusetts General Hospital
        • Kontakt:
      • Boston, Massachusetts, Forenede Stater, 02115
      • Danvers, Massachusetts, Forenede Stater, 01923
        • Mass General Cancer Center in Danvers
        • Kontakt:
      • Newton, Massachusetts, Forenede Stater, 02462
        • Mass General Cancer Center at Newton-Wellesley Hospital
        • Kontakt:
      • Waltham, Massachusetts, Forenede Stater, 02451

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Female or male patients ≥ 18 years of age.
  • Histologically confirmed diagnosis of invasive breast cancer after completion of definitive surgical management (either mastectomy or lumpectomy) within 3-12 weeks of starting study treatment.
  • Participants must have biopsy proven hormone receptor positive (HR+) (either/both estrogen receptor (ER) and progesterone receptor (PR) positive) HER2 negative (HER2-), invasive breast cancer. ER, PR, and HER2 positivity will be determined per ASCO/CAP guidelines by institutional (local) assessment, with expression of either the estrogen receptor (ER) or progesterone receptor (PR) at least 10%. Patients with multi-focal and multi-centric disease are eligible provided all histologically examined lesions are HR+/HER2- (local assessment). The need to biopsy additional lesions is per the discretion of the treating physician. Patients with bilateral invasive breast cancer are eligible provided all histologically examined lesions are HR+/HER2- (local assessment).
  • Anatomic stage IIB-III breast cancer according to AJCC 8th edition TNM staging, based on final surgical pathology. Patients with only lymph node micrometastases (pN1mi) are not eligible. Participants must have no evidence of distant metastatic disease (M0). Staging scans are not required and may be obtained at the discretion of the treating physician.
  • Both pre- and postmenopausal women are eligible.
  • ECOG performance status = 0, 1, 2 (Karnofsky ≥60%, see Appendix A)
  • Ability to understand and the willingness to sign a written informed consent form (ICF). Patient has signed the ICF prior to any screening procedures being performed and is able to comply with protocol requirements.
  • Patient has adequate bone marrow and organ function as defined by the following laboratory values at screening:
  • Absolute neutrophil count (ANC) ≥ 1,500 per mm3
  • Platelets ≥ 100,000 per mm3
  • Hemoglobin ≥9.0 g/dL
  • INR ≤1.5
  • Serum creatinine <1.5 mg/dL or creatinine clearance ≥50 mL/min
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5 x ULN
  • Total bilirubin ≤1.5 x ULN or in patients with well-documented Gilbert's Syndrome direct bilirubin ≤1.5 x ULN

Exclusion Criteria:

  • Inflammatory breast cancer or locally recurrent breast cancer
  • Participants currently receiving systemic therapy, including endocrine therapy, for any other malignancy or having received systemic therapy for a malignancy in the past 3 years
  • Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality including any of the following:
  • History of angina pectoris, symptomatic pericarditis, coronary artery bypass graft (CABG) or myocardial infarction within 6 months prior to study entry
  • History of cardiac failure, known cardiomyopathy (LVEF < 50%; new LVEF assessment is not specifically required for this trial), significant/symptomatic bradycardia, Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome or any of the following:
  • Known risk to prolong the QT interval or induce Torsade's de Pointes.
  • Uncorrected hypomagnesemia or hypokalemia.
  • Systolic Blood Pressure (SBP) >160 mmHg or <90 mmHg.
  • Bradycardia (heart rate <50 at rest), by ECG or pulse. On screening, inability to determine the QTcF interval on the ECG (i.e.: unreadable or not interpretable) or QTcF >470 screening ECG
  • Pregnant or breast-feeding women are excluded from this study because the safety of study regimen in this population is not established
  • Participants with well-controlled HIV infection are eligible if they are on stable antiretroviral therapy and have no evidence of uncontrolled infection. Participants with chronic hepatitis B infection are eligible if viral replication is adequately suppressed with antiviral therapy when indicated. Participants with hepatitis C infection are eligible if they have been successfully treated or have stable disease with no evidence of clinically significant hepatic dysfunction. Separate HIV, hepatitis B, or hepatitis C testing for this trial is not required unless clinically indicated.
  • Participants who are currently receiving chronic treatment with corticosteroids at a dose ≥ 10 mg of prednisone (or its glucocorticoid equivalent) per day (inhaled and topical steroids are allowed), or any other chronic immunosuppressive treatment that cannot be discontinued prior to starting study drug
  • Participants who are not good candidates for the study (as per investigator judgement)
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception throughout the study and for 6 months after the last dose of sacituzumab govitecan, 2 months after the last dose of docetaxel, and for 1 year after the last dose of cyclophosphamide. Male participants capable of impregnating a woman must use highly effective methods of contraception throughout the study and for 3 months after the last dose of sacituzumab govitecan and for 4 months after the last doses of docetaxel and cyclophosphamide. Women are considered post-menopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential. Barrier method plus spermicide alone is not considered highly effective contraception but could be combined with other highly effective contraception methods. Highly effective contraception methods include:
  • Total abstinence when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
  • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
  • Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception
  • Prior treatment involving topoisomerase-I targeting agents, including ADCs

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Sacituzumab Govitecan with Chemotherapy

Participants will be given sacituzumab govitecan (SG) at a pre-determined dose on days 1 and 8 of each 21-day cycle into their vein (by intravenous infusion). This will continue for up to 4 cycles. After completing 4 cycles of SG, participants will be given docetaxel and cyclophosphamide chemotherapy at the pre-determined doses on day 1 of each 21-day cycle into their vein. This will continue for up to 4 cycles, for a total of 8 treatment cycles from the start of treatment with SG.

Intravenous infusion administered on days 1 and 8 of cycles 1-4 (one cycle is 21 days).

Intravenous infusion administered on day 1 of cycles 5-8 (one cycle is 21 days).

Intravenous infusion administered on day 1 of cycles 5-8 (one cycle is 21 days).

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of Grade 3 or Higher Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: Screening to 2 years after completion of protocol therapy or until death, whichever occurs first.

TEAEs are defined/graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE); version in effect at study initiation. The proportion of patients experiencing at least 1 grade 3 or higher TEAE will be summarized both as a point estimate and by its respective 95% confidence interval. Statistical significance is declared at the one-sided 5% type I error by a two-stage binomial test. In addition to the estimation of the one-side 95% confidence interval around the grade 3 or higher TEAE rate, equivalent two-sided 90% confidence intervals will be estimated for better clinical interpretability.

Screening to 2 years after completion of protocol therapy or until death, whichever occurs first.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of Patients who Complete the Planned Study Regimen (Tolerability)
Tidsramme: Day first participant is enrolled to 2 years after the last participant completes protocol therapy.

Tolerability is defined as the proportion of patients who complete the planned study regimen without premature discontinuation due to toxicity. The completion rate and exact two-sided 95% confidence intervals will be reported. If all 32 patients are enrolled, the maximum half-width of the 95% confidence interval is approximately +/-0.18. Reasons for dose-reduction, delay, or discontinuation will be summarized.

Day first participant is enrolled to 2 years after the last participant completes protocol therapy.
2-Year Recurrence-Free Survival (RFS)
Tidsramme: Day 1 of cycle 1 (each cycle is 21 days) to 2 years after day 1 of cycle 1, day of documented disease recurrence, or death, whichever occurs first.

RFS is defined as the time from treatment initiation to documented invasive breast cancer recurrence (local, regional, or distant) or death from any cause, whichever occurs first. Participants alive without disease recurrence will be censored at the date of last disease evaluation. The 2-year RFS rate will be estimated using the Kaplan-Meier method. Given the short follow-up window and long duration of response of these patients, median RFS may not be achieved, at which point the probability for being recurrence free for 2 years will be estimated along with its respective 95% confidence interval (CI). Assuming 90% of the subjects are recurrence free at 2 years, the 95% CI is expected to extend approximately 17 percentage points below and 7 percentage points about the point estimate (approximately 73%-97%). Assuming an 80% 2-year RFS, the 95% CI is expected to extend approximately 18 percentage points below and 10 percentage points about the point estimate (approximately 62%-90%).

Day 1 of cycle 1 (each cycle is 21 days) to 2 years after day 1 of cycle 1, day of documented disease recurrence, or death, whichever occurs first.
Changes in Circulating tumor DNA (ctDNA) During and After Administration of Study Therapy
Tidsramme: Screening to 2 years after completion of protocol therapy or until death, whichever occurs first.

ctDNA will be analyzed longitudinally during treatment and follow-up using a general linear mixed model with a random intercept per subject and at minimum a fixed effect for time. ctDNA positively rates at predefined time points will be estimated and summarized. Changes in ctDNA allele fraction or tumor fraction over time will be summarized by slope and intercept estimates from the mixed model. 95% confidence interval will also be reported from the model.

Screening to 2 years after completion of protocol therapy or until death, whichever occurs first.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Laura Spring, MD, Massachusetts General Hospital

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

21. april 2027

Primær færdiggørelse (Anslået)

1. september 2028

Studieafslutning (Anslået)

1. september 2030

Datoer for studieregistrering

Først indsendt

13. november 2026

Først indsendt, der opfyldte QC-kriterier

13. november 2026

Først opslået (Faktiske)

19. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Request may be directed to: Dr. Laura Spring at 617-726-6500 or LSpring@mgh.harvard.edu. The protocol and statistical analysis plan will be made available on ClinicalTrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD-delingstidsramme

Data can be shared no earlier than 1 year following the date of publication.

IPD-delingsadgangskriterier

Contact the Partners Innovations team at http://www.partners.org/innovation

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner